Duk kana bukatar ka sani Game da Bugawa psoriasis jiyya

Wadatacce

• Sabon ilimin halittu
• Risankizumab-rzaa (Skyrizi)
• Maganin peertolizumab (Cimzia)
• Tildrakizumab-asmn (Ilumya)
• Distance Ga-Rankuwa-Guselkumab (Tremfya)
• Dadin Kowa (Siliq)
• Distance Ga-Rankuwa-Talxe (Taltz)
• Biosimilars
• Biosimilars zuwa adalimumab (Humira)
• Biosimilars zuwa etanercept (Enbrel)
• Biosimilars zuwa infliximab (Remicade)
• Sabbin magungunan yau da kullun
• Halobetasol propionate-tazarotene ruwan shafawa, 0.01% / 0.045% (Duobrii)
• Halobetasol propionate kumfa, 0.05% (Lexette)
• Halobetasol na maganin shafawa, 0.01% (Bryhali)
• Betamethasone dipropionate spray, 0.05% (Sernivo)
• Sabbin magunguna ga yara
• Kumfar Calcipotriene, 0.005% (Sorilux)
• Calcipotriene-betamethasone kumfa dipropionate, 0.005% / 0.064% (Enstilar)
• Calcipotriene-betamethasone dipropionate na dakatarwa, 0.005% / 0.064% (Taclonex)
• Ustekinumab (Stelara)
• Hanyar shiga (Enbrel)
• Sauran maganin da ke gab da amincewa
• Bimekizumab
• Calcipotriene-betamethasone dipropionate cream, 0.005% / 0.064% (Wynzora)
• JAK masu hanawa
• Awauki

Masu bincike sun koyi abubuwa da yawa a cikin 'yan shekarun nan game da cutar psoriasis da kuma rawar da garkuwar jiki ke takawa a wannan yanayin. Waɗannan sababbin abubuwan binciken sun haifar da aminci, da niyya, da maganin psoriasis mai tasiri.

Duk da hanyoyin kwantar da hankalin da ake dasu, karatu ya nuna cewa mutane da yawa da ke karbar magani don cutar psoriasis basu gamsu da maganin su ba ko kuma kawai sun gamsu da hakan.

Idan kana neman canza jiyya saboda wanda kakeyi yanzu baya da tasiri ko kuma kana da illoli, yana da kyau ka koyo gwargwadon iko game da sabbin hanyoyin.

Sabon ilimin halittu

Ana yin ilimin halittu ne daga abubuwan da aka samo su a cikin abubuwa masu rai, kamar su sunadarai, sugars, ko kuma nucleic acid. Da zarar cikin jiki, waɗannan magunguna suna toshe wani ɓangare na tsarin garkuwar jiki wanda ke ba da gudummawa ga alamun cututtukan ku na psoriasis.

Ilimin halittu ya tsoma baki tare da masu zuwa:

• ƙari necrosis factor alpha (TNF-alpha), wanda shine furotin wanda ke inganta ƙonewa cikin jiki
• Kwayoyin T, waxanda suke farin jini ne
• interleukins, waɗanda sune cytokines (ƙananan sunadaran kumburi) waɗanda ke cikin psoriasis

Wannan tsangwama yana taimakawa sauƙin kumburi.

Risankizumab-rzaa (Skyrizi)

Risankizumab-rzaa (Skyrizi) ta sami amincewar Hukumar Abinci da Magunguna (FDA) a watan Afrilu 2019.

An yi niyya ne ga mutanen da ke da matsakaiciyar cuta mai tsanani psoriasis waɗanda suke 'yan takara don maganin cutar shan magani (hasken haske) ko tsarin jiki (ko'ina).

Skyrizi yana aiki ta hanyar hana aikin interleukin-23 (IL-23).

Kowane kashi ya hada da allura biyu karkashin kasa (karkashin fata). Na farko allurai biyu suna tazara sati 4 tsakani. Sauran ana basu sau daya a kowane watanni 3.

Babban illolin Skyrizi sune:

• cututtuka na numfashi na sama
• halayen a wurin allurar
• ciwon kai
• gajiya
• cututtukan fungal

Maganin peertolizumab (Cimzia)

FDA ta amince da certolizumab pegol (Cimzia) a matsayin magani na psoriasis a watan Mayu 2018. An riga an amince da shi don magance yanayi kamar cutar Crohn da psoriatic arthritis (PsA).

Cimzia tana kula da cutar matsakaiciyar cuta mai tsanani a cikin mutane waɗanda suke candidatesan takarar neman maganin fototherapy ko tsarin warkewa. Yana aiki ta hanyar niyya furotin TNF-alpha.

Ana ba da maganin azaman allurai masu subcutaneous kowane mako.

Abubuwan da suka fi dacewa Cimzia sune:

• cututtuka na numfashi na sama
• kurji
• cututtukan urinary (UTIs)

Tildrakizumab-asmn (Ilumya)

Tildrakizumab-asmn (Ilumya) an amince da FDA a cikin watan Maris na 2018. An yi amfani da shi don magance alƙaluman psoriasis a cikin manya waɗanda ke neman takara don daukar hoto ko kuma tsarin tsari.

Magungunan yana aiki ta hanyar toshe IL-23.

Ana ba da Ilumya azaman injeji na karkashin jiki. Allurai na farko guda biyu suna tazara sati 4 tsakani. Daga nan zuwa gaba, allurai ana ba su wata 3 tsakanin juna.

Babban illolin Ilumya sune:

• halayen a wurin allurar
• cututtuka na numfashi na sama
• gudawa

Distance Ga-Rankuwa-Guselkumab (Tremfya)

Guselkumab (Tremfya) an amince da ita a watan Yulin 2017. An yi amfani da shi don magance matsakaiciyar cuta mai tsanani a cikin mutane waɗanda su ma 'yan takara ne don maganin fototherapy ko tsarin tsarin.

Tremfya shine farkon ilimin ilimin halittar jiki don ƙaddamar da IL-23.

Ana ba da farkon farawa biyu na sati huɗu. Bayan haka, ana ba da Tremfya a matsayin allurar subcutaneous kowane mako 8.

Abubuwan da suka fi dacewa sun haɗa da:

• ciwon kai
• cututtuka na numfashi na sama
• halayen a wurin allurar
• ciwon gwiwa
• gudawa
• ciwon ciki

Dadin Kowa (Siliq)

Brodalumab (Siliq) an amince da FDA ne a cikin watan Fabrairun 2017. An tsara shi ne don mutanen da suka cika ƙa'idodi masu zuwa:

• da matsakaici zuwa mai tsanani plaque psoriasis
• 'yan takara ne don daukar hoto ko kuma tsarin tsari
• psoriasis ɗinsu baya amsawa ga sauran hanyoyin warkewar tsarin

Yana aiki ta ɗaure ga mai karɓar IL-17. Hanyar IL-17 tana taka rawa cikin kumburi kuma tana da hannu wajen haɓaka alamun alamun psoriasis.

A cikin gwaji na asibiti, mahalarta da aka yiwa jiyya tare da Siliq sun fi waɗanda suka sami placebo samun fata wanda aka ɗauka a sarari ko kusan bayyanannu.

Ana amfani da Siliq a matsayin allura. Idan likitanku ya ba da shawarar maganin, za ku karɓi allura sau ɗaya a mako don makonni 3 na farko. Bayan haka, zaku sami allura guda ɗaya kowane sati 2.

Kamar sauran ilimin ilimin halittu, Siliq yana ƙara haɗarin kamuwa da ku. Alamar wannan magani kuma tana da gargaɗin akwatin baƙar fata game da haɗarin tunani da halaye na kisan kai mafi girma.

Ya kamata a kula da mutanen da ke da tarihin halaye na kunar-bakin-wake ko ɓacin rai yayin shan brodalumab.

Distance Ga-Rankuwa-Talxe (Taltz)

Ixekizumab (Taltz) an amince da FDA a cikin Maris 2016 don kula da manya da matsakaici zuwa mai tsanani psoriasis. An yi niyya ne ga mutanen da suke candidatesan takarar neman daukar hoto, gyaran jiki, ko kuma duka biyun.

Taltz yana ƙaddamar da furotin IL-17A.

Magungunan allura ne. Za ku sami allura biyu a ranarku ta farko, allura kowane mako 2 don watanni 3 masu zuwa, da allura kowane mako 4 don ragowar maganin ku.

Yarda ya dogara ne akan sakamakon karatun asibiti da yawa tare da duka mahalarta 3,866. A cikin waɗannan karatun, yawancin mutane da ke shan ƙwayoyi sun sami fata wanda ya kasance bayyananne ko kusan bayyane.

Abubuwan da suka fi dacewa na Taltz sun haɗa da:

• cututtuka na numfashi na sama
• halayen a wurin allurar
• cututtukan fungal

Biosimilars

Biosimilars ba ainihin kayan aikin ilimin halittu bane. Madadin haka, an sake sarrafa su ta baya don samar da sakamako iri ɗaya kamar ilimin kimiyyar halittu.

Kamar magungunan ƙwayoyi, biosimilars ana yin su ne da zarar asalin ilimin halitta ya fita daga haƙƙin mallaka. Amfani da biosimilars shine cewa galibi suna da tsada sosai fiye da samfurin asali.

Biosimilars don psoriasis sun haɗa da masu zuwa:

Biosimilars zuwa adalimumab (Humira)

• adalimumab-adaz (Hyrimoz)
• adalimumab-adbm (Cyltezo)
• adalimumab-afzb (Abrilada)
• adalimumab-atto (Amjevita)
• adalimumab-bwwd (Hadlima)

Biosimilars zuwa etanercept (Enbrel)

• anarin-szzs (Erelzi)
• yarbanan-ykro (Eticovo)

Biosimilars zuwa infliximab (Remicade)

• infliximab-abda (Renflexis)
• infliximab-axxq (Avsola)
• infliximab-dyyb (Tsinkaya)

The Remicade biosimilar Inflectra shine farkon psoriasis biosimilar don karɓar amincewar FDA. Ya kasance a cikin Afrilu 2016.

Inflectra da Renflexis, wani Remicade biosimilar, sune kawai waɗanda a halin yanzu ake samun sayan su a Amurka. Wannan shi ne farko saboda takaddun haƙƙin mallaka waɗanda masana'antun kimiyyar halittu ke riƙewa har yanzu bai ƙare ba.

Sabbin magungunan yau da kullun

Magunguna na yau da kullun, ko waɗanda kuke shafawa akan fatar ku, galibi sune magunguna na farko da likitoci ke ba da shawarar psoriasis. Suna aiki ta rage rage kumburi da rage yawan kwayar halitta.

Halobetasol propionate-tazarotene ruwan shafawa, 0.01% / 0.045% (Duobrii)

A watan Afrilun 2019, FDA ta amince da maganin shafawa na halobetasol propionate-tazarotene, kashi 0.01 / 0.045 (Duobrii) don maganin cutar al'aurar psoriasis a cikin manya.

Duobrii shine ruwan farko don hada corticosteroid (halobetasol propionate) tare da retinoid (tazarotene). Corticosteroid mai cike da kumburi yana kawar da alamomi, yayin da bitamin A da ke kan gaba na retinoid yana iyakance haɓakar ƙwayoyin fata.

Ana amfani da Duobrii sau ɗaya a rana zuwa wuraren fata.

Babban illolin sune:

• zafi a shafin aikace-aikacen
• kurji
• folliculitis, ko kumburin kumburin gashi
• sa fata daga inda ake shafa ruwan shafa fuska
• excoriation, ko tarawar fata

Halobetasol propionate kumfa, 0.05% (Lexette)

Halobetasol propionate foam, kashi 0.05 shine corticosteroid na kan layi wanda FDA ta fara amincewa dashi, a matsayin na kwaya, a watan Mayu 2018. A watan Afrilu 2019, ya zama ana samu a ƙarƙashin sunan Lexette.

Ana amfani dashi don magance cutar al'aurar psoriasis a cikin manya. Manufarta ita ce share fata.

Sau biyu a rana, ana amfani da kumfa a cikin siraran siriri sannan a shafa shi cikin fata. Ana iya amfani da lexette na tsawon sati 2.

Abubuwan illa na yau da kullun na Lexette shine ciwo a wurin aikace-aikacen da ciwon kai.

Halobetasol na maganin shafawa, 0.01% (Bryhali)

Halobetasol propionate ruwan shafawa, kashi 0.01 (Bryhali) FDA ta amince da shi a cikin Nuwamba Nuwamba 2018. An yi niyya ne don manya da ke dauke da cutar psoriasis.

Wasu daga cikin alamun da yake taimakawa magance su sune:

• rashin ruwa
• flaking
• kumburi
• plaque buildup

Ana amfani da Bryhali a kullum. Ana iya amfani da ruwan shafawar na tsawon sati 8.

Sakamakon illa mafi yawan gaske sun haɗa da:

• konawa
• harbawa
• ƙaiƙayi
• rashin ruwa
• cututtuka na numfashi na sama
• hawan jini

Betamethasone dipropionate spray, 0.05% (Sernivo)

A watan Fabrairun 2016, FDA ta amince da feshin maganin betamethasone dipropionate, kashi 0.05 (Sernivo). Wannan jigo yana magance cutar psoriasis mai laushi zuwa matsakaici a cikin mutane masu shekaru 18 zuwa sama.

Sernivo yana taimakawa wajen taimakawa bayyanar cututtukan psoriasis kamar ƙaiƙayi, flaking, da redness.

Kuna fesa wannan maganin corticosteroid akan fata sau biyu a rana kuma a hankali shafa shi. Ana iya amfani da shi har zuwa makonni 4.

Sakamakon illa mafi yawan sune:

• ƙaiƙayi
• konawa
• harbawa
• zafi a shafin aikace-aikacen
• atrophy na fata

Sabbin magunguna ga yara

Wasu psoriasisan magungunan psoriasis waɗanda a baya kawai ake samu don manya sun sami izinin FDA kwanan nan don kula da yara ma.

Kumfar Calcipotriene, 0.005% (Sorilux)

A cikin 2019, FDA ta faɗaɗa amincewarsa don wani nau'in bitamin D da ake kira kumfa calcipotriene, kashi 0.005 (Sorilux). Ana amfani da shi don maganin cutar al'aurar psoriasis na fatar kan mutum da na jiki.

A watan Mayu, ta karɓi izinin amfani da yara 'yan shekara 12 zuwa 17. A watan Nuwamba mai zuwa, an amince da shi don magance cutar al'aura ta fatar kan mutum da ta jiki a cikin yara tun suna 'yan shekaru 4 da haihuwa.

Sorilux yana taimakawa jinkirin haɓakar ƙwayar ƙwayar fata mara kyau a cikin psoriasis. Ana amfani da wannan kumfa a wuraren da fatar ta shafa sau biyu a rana har zuwa makonni 8. Idan bayyanar cututtuka ba ta inganta ba bayan makonni 8, tuntuɓi likitanka.

Abubuwan illa mafi yawan gaske sune redness da zafi a shafin aikace-aikacen.

Calcipotriene-betamethasone kumfa dipropionate, 0.005% / 0.064% (Enstilar)

A watan Yulin 2019, FDA ta amince da kumfar calcipotriene-betamethasone dipropionate, kashi 0,005 / 0.064 (Enstilar) don amfani a cikin samari tsakanin 12 da 17 shekaru. An yi niyya ne don mutanen da ke dauke da almarar psoriasis.

Calcipotriene yana jinkirin haɓakar ƙwayar fata, yayin da betamethasone dipropionate yana taimakawa rage ƙonewa.

Ana amfani da kumfa a kullun har zuwa makonni 4.

Sakamakon illa mafi yawan gaske sun haɗa da:

• ƙaiƙayi
• folliculitis
• kurji tare da ɗauke da kumburi ja ko amya
• damuwa psoriasis

Calcipotriene-betamethasone dipropionate na dakatarwa, 0.005% / 0.064% (Taclonex)

A watan Yulin 2019, calcipotriene-betamethasone dipropionate Topical dakatar, 0.005 kashi / 0.064 bisa dari (Taclonex) an kuma amince da FDA don amfani a cikin shekaru 12 zuwa 17 tare da plaque psoriasis na jiki.

Babban dakatarwar da aka riga an yarda da ita ta FDA don shekaru 12 zuwa 17 tare da allon psoriasis na fatar kan mutum. Wani maganin shafawa na Taclonex an riga an sami izinin FDA don matasa da manya tare da rubutun psoriasis.

Ana amfani da dakatarwar Taclonex na yau da kullun har zuwa makonni 8. Ga 'yan shekaru 12 zuwa 17, matsakaicin satin sati shine 60 gram (g). Matsakaicin iyakar mako-mako na manya shine 100 g.

Sakamakon illa mafi yawan gaske sun haɗa da:

• ƙaiƙayi
• konawa
• hangula
• ja
• folliculitis

Ustekinumab (Stelara)

A watan Oktoba 2017, FDA ta amince da ustekinumab (Stelara) don matasa masu shekaru 12 zuwa sama. Ana iya amfani dashi don samari masu matsakaitan cuta mai tsanani psoriasis waɗanda suke candidatesan takarar neman daukar hoto ko kuma tsarin tsari.

Amincewar ta zo ne bayan binciken da aka gudanar a shekara ta 2015 wanda ya gano cewa maganin ya share fatar sosai bayan watanni 3. Dangane da gyaran fata da aminci, sakamako ya kasance kama da na waɗanda aka gani a cikin manya.

Stelara ta toshe sunadarai guda biyu waɗanda ke mabuɗin tsarin kumburi, IL-12 da IL-23.

An bayar dashi azaman allurar subcutaneous. Yin amfani yana dogara ne akan nauyin jiki:

• Matasan da suka gaza kilogram 60 (fan 132) suna samun milligrams 0.75 (MG) a kowace kilogram na nauyi.
• Matasan da suka auna tsakanin kilo 60 (132 lbs.) Da 100 kg (220 lbs.) Sun sami kashi 45-mg.
• Matasan da suka auna fiye da kilogiram 100 (220 lbs.) Sun sami 90 MG, wanda shine madaidaicin kashi na manya na wannan nauyin.

An ba da allurai biyu na farko makonni 4 dabam. Bayan wannan, ana ba da magani sau ɗaya a kowane watanni 3.

Sakamakon illa mafi yawan sune:

• mura da sauran cututtukan fili na sama
• ciwon kai
• gajiya

Hanyar shiga (Enbrel)

A watan Nuwamba na 2016, FDA ta amince da yaduwar cutar (Enbrel) don magance cutar matsakaiciyar cuta zuwa yara masu shekaru 4 zuwa 17 waɗanda ke neman takara ta hanyar maganin fototherapy ko tsarin tsari.

An yarda Enbrel ya bi da manya tare da allon psoriasis tun daga 2004 kuma ya bi da yara da ke fama da cututtukan cututtukan yara (JIA) tun daga 1999.

Wannan maganin allurar yana aiki ta rage ayyukan TNF-alpha.

Nazarin 2016 game da yara kusan 70 masu shekaru 4 zuwa 17 sun gano cewa Enbrel yana cikin aminci kuma ya ci gaba da aiki har zuwa shekaru 5.

Kowane mako, yara da matasa suna karɓar MG na 0.8 na magani a kowace kilogram na nauyin jikinsu. Matsakaicin iyakar da likitansu zai rubuta shi ne 50 MG a kowane mako, wanda shine madaidaicin kashi ga manya.

Illolin da aka fi sani sune ra'ayoyi a wurin allura da cututtukan fili na sama.

Sauran maganin da ke gab da amincewa

Sauran kwayoyi suna kusa da izinin FDA.

Bimekizumab

Bimekizumab magani ne na allurar ƙwayoyin cuta wanda ake gwada shi azaman magani don maganin cutar psoriasis na yau da kullun. Yana aiki ta hanyar toshe IL-17.

Bimekizumab a halin yanzu yana cikin karatun zamani na III. Ya zuwa yanzu, bincike ya nuna shi lafiya da tasiri.

A cikin gwajin gwaji na BE SURE, bimekizumab ya fi adalimumab inganci (Humira) wajen taimaka wa mutane su sami aƙalla ci gaban kashi 90 cikin ɗari da aka yi amfani da su don auna tsananin cutar.

Calcipotriene-betamethasone dipropionate cream, 0.005% / 0.064% (Wynzora)

A cikin 2019, an gabatar da sabon aikace-aikacen magani ga FDA don Wynzora. Wynzora shine kirim mai sau ɗaya wanda yake haɗuwa da calcipotriene da betamethasone dipropionate.

A cikin binciken kashi na III, Wynzora ya fi tasiri wajen share fata bayan makonni 8 fiye da dakatarwar Taclonex da cream.

Wynzora yana da fa'idar zama ba matsala, wanda mahalarta binciken suka gano sun fi dacewa.

JAK masu hanawa

JAK masu hanawa wani rukuni ne na magungunan canza cuta. Suna aiki ta hanyar niyya hanyoyin da suke taimakawa jiki don samar da ƙarin sunadarai masu kumburi.

An riga an yi amfani dasu don bi da:

• cututtukan zuciya na psoriatic
• rheumatoid amosanin gabbai
• ulcerative colitis

Kadan suna cikin lokaci na II da na III na gwaji don matsakaici zuwa mai tsanani psoriasis. Wadanda ake karantar su game da cutar psoriasis sune magungunan tofacitinib (Xeljanz), baricitinib (Olumiant), da abrocitinib. Ana kuma bincika mai hana JAK na kan layi.

Ya zuwa yanzu, karatu ya gano masu hana JAK yin tasiri ga psoriasis. Suna da lafiya kamar magungunan ƙwayoyin halitta. Wata fa'ida ita ce sun zo a cikin kwaya kuma ba lallai ne a ba su allura ba.

Karatun da aka yi ya zuwa yanzu ɗan gajeren lokaci ne. Ana buƙatar ƙarin bincike don sanin ko masu hana JAK ci gaba da yin tasiri a cikin dogon lokaci.

Awauki

Kasancewa game da sababbin zaɓuɓɓuka don magance cutar psoriasis yana da mahimmanci don kula da yanayinku.

Babu wani magani daya-dace-duka don psoriasis. Wataƙila za ku gwada magunguna daban-daban kafin ku sami wanda zai fi dacewa da ku kuma baya haifar da illa.

Sabbin abubuwa a cikin cutar psoriasis suna faruwa koyaushe. Tabbatar yin magana da likitanka game da sababbin zaɓuɓɓukan magani.